secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
CIK:        0001979414
Form:       8-K
Filed at:   2025-12-17T23:59:59+00:00
Accession:  0001829126-25-010101
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeOnc reports updated NEO100 data: 24% radiographic remission, 44% PFS-6 in recurrent IDH1-mutant astrocytoma
--------------------------------------------------------------------------------

- 6 of 25 patients (24%) achieved radiographic remission vs <8% historical salvage therapies.
- 44% achieved 6-month progression-free survival (PFS-6), exceeding historical 21-31% benchmarks.
- 9 of 25 patients (36%) remain alive ≥18 months post NEO100 initiation; no significant toxicity seen.
- All patients had recurrent WHO Grade III/IV IDH1-mutant astrocytoma; data from Phase 1/2a and compassionate use.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1979414/000182912625010101/0001829126-25-010101-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1979414/000182912625010101/neonctechnologies_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-25-010101

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer